BIOMUNEX 

PHARMACEUTICALS

Partnering structure : 

  • Exclusive worldwide license and co-development agreement  

  • Strategic equity investment

 

Biomunex Pharmaceuticals is a biopharmaceutical company, based in Paris, France and Cambridge, MA, USA, focused on the discovery and development of breakthrough immunotherapies using its unique and proprietary BiXAb® technology to create next generation bi- and multi-specific antibodies for immuno-oncology.  ‘Plug-and-Play’ BiXAb technology produces bi- and multi-specific antibodies, with minimal engineering, from any pair of monoclonal antibodies as building blocks, in a timely and cost-effective manner.

EMERCell

Partnering structure : 

  • Strategic equity investment  

  • Onward to become future majority shareholder

 

Onward works in collaboration with EMERCell who have developed generic cell immunotherapy derived from Natural Killer (NK) cells, to be used in synergy with antibodies.

EMERCell is a biopharmaceutical company located in Montpellier, France with laboratories at the IRMB (Institute of Regenerative Medicine and Biotherapies) within Saint-Eloi University Hospital Center, Montpellier, France.